Does CT overestimate extra-pancreatic perineural invasion in patients with pancreatic ductal adenocarcinoma following neoadjuvant chemoradiation therapy?

被引:1
|
作者
Noda, Yoshifumi [1 ,2 ]
Pisuchpen, Nisanard [1 ,3 ]
Parakh, Anushri [1 ]
Srinivas-Rao, Shravya [4 ,5 ]
Kinowaki, Yuko [4 ,5 ]
Mino-Kenudson, Mari [4 ,5 ]
Kambadakone, Avinash R. [1 ,6 ]
机构
[1] Harvard Med Sch, Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA
[2] Gifu Univ, Dept Radiol, Gifu 5011194, Japan
[3] Chulalongkorn Univ, King Chulalongkorn Mem Hosp, Fac Med, Dept Radiol, Bangkok 10330, Thailand
[4] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA
[5] Harvard Med Sch, Boston, MA 02114 USA
[6] Harvard Med Sch, Massachusetts Gen Hosp, Dept Radiol, White 270,55 Fruit St, Boston, MA 02114 USA
来源
BRITISH JOURNAL OF RADIOLOGY | 2024年 / 97卷 / 1155期
关键词
extra-pancreatic perineural invasion; pancreatic ductal adenocarcinoma; computed tomography; CANCER; CHEMOTHERAPY; FOLFIRINOX; BORDERLINE;
D O I
10.1093/bjr/tqae001
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Objectives To evaluate the diagnostic performance of CT in the assessment of extra-pancreatic perineural invasion (EPNI) in patients with pancreatic ductal adenocarcinoma (PDAC).Methods This retrospective study included 123 patients (66 men; median age, 66 years) with PDAC who underwent radical surgery and pancreatic protocol CT for assessing surgical resectability between September 2011 and March 2019. Among the 123 patients, 97 patients had received neoadjuvant chemoradiation therapy (CRT). Two radiologists reviewed the CT images for evidence of EPNI using a 5-point scale (5 = definitely present, 4 = probably present, 3 = equivocally present, 2 = probably absent, and 1 = definitely absent). Diagnostic performance for assessing EPNI was evaluated with receiver operating characteristic (ROC) curve analysis.Results The sensitivity, specificity, and area under the ROC curve for assessing EPNI were 98%, 30%, and 0.62 in all patients; 97%, 22%, and 0.59 in patients with neoadjuvant CRT; and 100%, 100%, and 1.00 in patients without neoadjuvant CRT, respectively. False-positive assessment of EPNI occurred in 23% of patients (n = 28/123), and 100% of these (n = 28/28) had received neoadjuvant CRT. There was moderate to substantial agreement between the readers (kappa = 0.49-0.62).Conclusion Pancreatic protocol CT has better diagnostic performance for determination of EPNI in treatment naive patients with PDAC and overestimation of EPNI is likely in patients who have received preoperative CRT.Advances in Knowledge Pancreatic protocol CT has better diagnostic performance for the detection of EPNI in treatment naive patients compared to patients receiving neoadjuvant CRT.
引用
收藏
页码:607 / 613
页数:7
相关论文
共 50 条
  • [21] Hallmarks of perineural invasion in pancreatic ductal adenocarcinoma: new biological dimensions
    Sun, Yaquan
    Jiang, Wei
    Liao, Xiang
    Wang, Dongqing
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [22] Neoadjuvant Chemoradiation Therapy in Borderline Resectable Pancreatic Adenocarcinoma
    Shafi, S.
    Kaubisch, A.
    PANCREAS, 2015, 44 (08) : 1413 - 1413
  • [23] The Effects of Neoadjuvant Chemoradiation on Gene Expression Patterns of Pancreatic Ductal Adenocarcinoma
    Baschnagel, A. M.
    Stone, B. M.
    Thibodeau, B. J.
    Fortier, L. E.
    Ahmed, S.
    Geddes, T. J.
    Ketelsen, B. E.
    Pruetz, B. L.
    Jury, R. P.
    Wilson, G. D.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S360 - S361
  • [24] Patient Preferences for Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma
    Hamad, Ahmad
    Crossnohere, Norah
    Ejaz, Aslam
    Tsung, Allan
    Pawlik, Timothy M.
    Sarna, Angela
    Santry, Heena
    Wills, Celia
    Cloyd, Jordan M.
    PANCREAS, 2022, 51 (06) : 657 - 662
  • [25] Trends in the utilization of neoadjuvant therapy for pancreatic ductal adenocarcinoma
    Brown, Zachary J.
    Cloyd, Jordan M.
    JOURNAL OF SURGICAL ONCOLOGY, 2021, 123 (06) : 1432 - 1440
  • [26] Incidence of pancreatic and extra-pancreatic cancers in the families of patients with pancreatic adenocarcinoma:: Results of prospective survey.
    Audibert, AMM
    Rufat, P
    Chayvialle, JA
    Maire, F
    O'Toole, D
    Hammel, P
    Hentic, O
    Lévy, P
    Ruszniewski, P
    GASTROENTEROLOGY, 2002, 122 (04) : A566 - A566
  • [27] Inhibition of SREBP1 Suppresses Perineural Invasion in Pancreatic Ductal Adenocarcinoma
    Xiao, Y.
    Wang, Z.
    Ma, Q. Y.
    PANCREAS, 2019, 48 (10) : 1548 - 1548
  • [28] Perineural Invasion in Pancreatic Ductal Adenocarcinoma (PDAC): A Saboteur of Curative Intended Therapies?
    Felsenstein, Matthaus
    Lindhammer, Flora
    Feist, Mathilde
    Hillebrandt, Karl Herbert
    Timmermann, Lea
    Benzing, Christian
    Globke, Brigitta
    Zocholl, Dario
    Hu, Mengwen
    Fehrenbach, Uli
    Sinn, Bruno Valentin
    Pelzer, Uwe
    Sauer, Igor Maximillian
    Pratschke, Johann
    Malinka, Thomas
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (09)
  • [29] Quantification of perineural invasion in pancreatic ductal adenocarcinoma: proposal of a severity score system
    Lena, Marco Schiavo
    Gasparini, Giulia
    Crippa, Stefano
    Belfiori, Giulio
    Aleotti, Francesca
    Di Salvo, Francesca
    Redegalli, Miriam
    Cangi, Maria Giulia
    Taveggia, Carla
    Falconi, Massimo
    Doglioni, Claudio
    VIRCHOWS ARCHIV, 2023, 483 (02) : 225 - 235
  • [30] Quantification of perineural invasion in pancreatic ductal adenocarcinoma: proposal of a severity score system
    Marco Schiavo Lena
    Giulia Gasparini
    Stefano Crippa
    Giulio Belfiori
    Francesca Aleotti
    Francesca Di Salvo
    Miriam Redegalli
    Maria Giulia Cangi
    Carla Taveggia
    Massimo Falconi
    Claudio Doglioni
    Virchows Archiv, 2023, 483 : 225 - 235